BSXBSX: Wichmann Named Lead Independent Director
Boston Scientific says Wichmann will succeed Ludwig as Lead Independent Director on Jan. 1, 2027.
BOSTON SCIENTIFIC CORP
BSXBSX: Boston Scientific Names New COO, CFO
Boston Scientific (BSX) promotes Joe Fitzgerald to COO and appoints Mark Bickel as CFO successor to Woodworth. Company updates amid recent cyber incident.
BOSTON SCIENTIFIC CORP
BSXBSX: Arthur Butcher to Retire Jan 1, 2027
Boston Scientific (BSX) EVP and Group President Arthur C. Butcher will retire effective 1/1/2027. Key investor implications and company context.
BOSTON SCIENTIFIC CORP
BSXBoston Scientific Lowers 2026 Earnings Guidance
Boston Scientific (BSX) lowers Q3 and full-year 2026 earnings guidance after Aug 26 cybersecurity incident disrupted operations.
BOSTON SCIENTIFIC CORP
BSXBSX: Global Cybersecurity Incident Disrupts Operations
Boston Scientific (BSX) reports a global cyber incident disrupting IT systems and order processing; investors should watch company disclosures.
BOSTON SCIENTIFIC CORP
BSXBoston Scientific Approves Global Restructuring
BSX launches a global restructuring on 2026-07-27 to cut costs and support growth amid planned acquisition and refinancing.
BOSTON SCIENTIFIC CORP
BSXBoston Scientific Secures $11B Credit Facilities
Boston Scientific (BSX) arranges $11B in credit facilities to refinance debt and fund an acquisition. Implications for liquidity, leverage and capital allocation as of 2026-02-26.
BOSTON SCIENTIFIC CORP
BSXBoston Scientific to Acquire Penumbra (BSX)
Boston Scientific (BSX) announces intent to acquire Penumbra via merger. Read a concise investor-focused summary and context as of 2026-02-26.
BOSTON SCIENTIFIC CORP
BSXBSX: Boston Scientific Board Expands to 12
Boston Scientific (BSX) expands its board to 12 with two new directors; two directors are scheduled to retire at the 2026 annual meeting.
BOSTON SCIENTIFIC CORP
BSXBoston Scientific Expands Buyback to $5B
Boston Scientific's board approved a $4B increase to its stock repurchase program, expanding authorization to $5B. Investor-focused context and risks.
BOSTON SCIENTIFIC CORP
BSXBSX: Director John Sununu to Leave in 2026
Boston Scientific director John Sununu will not seek re-election at the 2026 annual meeting — implications for board succession and investors.
BOSTON SCIENTIFIC CORP
BSXBoston Scientific (BSX) Completes Key Acquisitions
Boston Scientific (BSX) acquires Nalu Medical and assets from Elutia, bolstering MedSurg and cardiovascular product pipeline and M&A-driven growth strategy.
BOSTON SCIENTIFIC CORP
BSXBSX Q3 2025: Revenue Beats Guidance
Boston Scientific (BSX) Q3 2025 sales rose 20.3% to $5.065B; EPS $0.75 exceeded forecasts. Read key drivers, segment context, and investor considerations.
BOSTON SCIENTIFIC CORP
BSXBSX Raises 2025 Earnings Guidance
Boston Scientific (BSX) raises its 2025 sales and EPS outlook. Analysis of drivers, segment exposure (Cardiovascular, MedSurg), risks, and investor implications.
BOSTON SCIENTIFIC CORP
BSXBSX: Boston Scientific Restructures After Valve Cut
Boston Scientific (BSX) announces restructuring after discontinuing the ACURATE valve system. Analysis of segment impact, risks and strategic implications.
BOSTON SCIENTIFIC CORP
BSXBSX: FARAPULSE Approved in Japan for Persistent AF
Boston Scientific's FARAPULSE PFA system gains approval in Japan to treat persistent atrial fibrillation, supporting electrophysiology growth and APAC expansion.
BOSTON SCIENTIFIC CORP